Sign up Australia
Proactive Investors - Run By Investors For Investors

Uscom 'on the cusp of releasing seven new products into global markets'

Uscom Ltd (ASX:UCM) founder, chairman and chief executive Rob Phillips speaks to Proactive Investors about the cardiovascular-pulmonary medical device producer's expanding global operations and product offering.

The company is obtaining final approvals to launch new products in Australia, China, Europe and the USA. Phillips explains, "what that will give us is a diversified suite of novel products that are sector-leading and quite revolutionary in cardiac output, vascular assessment, and in pulmonary/respiratory... our products basically assist the management and care of patients that have diseases which kill 75% of the world's population, so they are massively relevant. Heart failure, sepsis, asthma, COPD, hypertension; these are diseases that are in our space, so we've got a really strong underwritten clinical need."

"We've been growing at 30-40% per annum, and that's with one product. And we're on the cusp now of releasing seven new products into global markets... we're looking forward to the next two to three years, and taking investors with us on that journey, because we will transform from being a small Australian biotech to being a significant international biotechnology company," says Phillips.

 
Meet Arix Bioscience Plc, Avacta Group Plc and Silence Therapeutics plc at our event, London , 04 October 2018. Register here »
View full UCM profile View Profile

Uscom Ltd Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use